1. Clinical & Scientific Overview
Erythropoietin Alfa (rHuEPO) & Darbepoetin Alfa (TIP-MED-000391, Reference Code [10.15]-CMP121) is classified under
Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10) as a Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Complexes (Schedule H | NLEM 2022 [Iron Sucrose] | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.
4. Therapeutic Indications & Evidence-Supported Uses
- Moderate-to-severe Iron Deficiency Anaemia (IDA) when oral iron is ineffective, not tolerated, or rapid replenishment is clinically required: 2nd and 3rd trimesters of pregnancy (Hb 5
- 0 g/dL per MoHFW AMB guidelines), postpartum anaemia, CKD, HFrEF with iron deficiency (ferritin <100 ng/mL), IBD, and heavy uterine bleeding
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-12-14). Recombinant ESAs (Zyrop, Cresp; Cold Chain 2°C–8°C) for CKD anaemia; requires prior iron repletion (TSAT >20%, Ferritin >100 ng/mL) and Hb target cap <=11.0–11.5 g/dL.
Administration & Meal Timing: STRICT DILUTION & OVER-DILUTION RULE: Dilute ONLY in sterile 0.9% Sodium Chloride (Normal Saline) — NEVER dilute in Dextrose (D5W) or over-dilute FCM to <2 mg Fe/mL! STOP oral iron tablets for at least 5 days after IV iron! | Single-session infusion (FCM 500–1000 mg) or Divided sessions (Iron Sucrose 200 mg q48–72h)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [10.15].
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in the 1ST TRIMESTER OF PREGNANCY (use only in 2nd & 3rd trimesters!), non-iron-deficiency anaemia (thalassaemia major, haemochromatosis), active bacteraemia/sepsis, and history of severe parenteral iron hypersensitivity. Resuscitation equipment (Adrenaline 1:1000 IM) MUST be at bedside and patient observed for 30 minutes post-infusion!
Key Clinical Precautions: Renal: Safe and foundational in CKD & dialysis (Iron Sucrose has a lower risk of FGF23-induced hypophosphataemia than FCM!). Hepatic: Caution in decompensated cirrhosis or iron overload
8. Adverse Effects Profile
- Nausea, transient metallic taste, flushing, headache, mild arthralgia/myalgia 24–48h post-infusion, Fishbane reaction (transient chest/back tightness that resolves within minutes of pausing the infusion — restart at 50% slower rate after 15 min!)
- HYPOPHOSPHATAEMIA & OSTEOMALACIA WITH FERRIC CARBOXYMALTOSE (FCM): FCM uniquely induces a sharp rise in intact FGF23, causing renal phosphate wasting and symptomatic hypophosphataemia (<2.0 mg/dL -> fatigue, muscle weakness, & osteomalacia!). Also: True anaphylaxis, and permanent dark brown skin staining (tattoo) if IV line extravasates!
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Parenteral iron blocks oral iron absorption for >=5 days — discontinue oral Ferrous Sulfate/Ascorbate before giving IV iron! ACE inhibitors increase incidence of systemic flushing/hypotensive reactions during IV iron infusion
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [10.15].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: FOUR VITAL CLINICAL & COUNTER RULES: (1) Never give IV iron in the 1st trimester of pregnancy (safe in 2nd & 3rd trimesters); (2) Never give more than 200 mg of Iron Sucrose (Orofer S) in a single day (whereas FCM [Encicarb/Orofer FCM] can be given as 500–1000 mg in a single 20-minute drip); (3) Dilute ONLY in Normal Saline (never Dextrose!); (4) Stop taking oral iron tablets when receiving an IV iron drip
- Meal & Clock Timing Instruction: STRICT DILUTION & OVER-DILUTION RULE: Dilute ONLY in sterile 0.9% Sodium Chloride (Normal Saline) — NEVER dilute in Dextrose (D5W) or over-dilute FCM to <2 mg Fe/mL! STOP oral iron tablets for at least 5 days after IV iron! (Single-session infusion (FCM 500–1000 mg) or Divided sessions (Iron Sucrose 200 mg q48–72h))
- Missed Dose Protocol: Single/scheduled clinic infusion
- Geriatric Dispensing Pearl: Highly effective in older adults with HFrEF, CKD, or GI malabsorption/angiodysplasia who cannot tolerate oral iron
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Ferric Carboxymaltose (FCM) Vials: 500 mg/10 mL, 1000 mg/20 mL (50 mg Fe/mL). Iron Sucrose Ampoules: 100 mg/5 mL (20 mg Fe/mL)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.15]-C120 Iron Sucrose (Parenteral IV Iron) — Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Comp
- [10.7] Oral Iron Salts (Ferrous Sulphate, Ferrous Ascorbate & Ferrous Fumarate) — Oral Divalent (Fe2+) & Parenteral Trivalent (Fe3+) Haematinic Min
- [10.8] Folic Acid (Vitamin B9 / Pteroylglutamic Acid) (and L-Methylfolate) — Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essen
- [10.15] Ferric Carboxymaltose (FCM) & Iron Sucrose (Parenteral Intravenous Iron) — Colloidal Macromolecular Carbohydrate-Shell Intravenous Iron Comp